# Hematology Sector

Canonical URL: https://biopharmsignal.com/sector/hematology

Hematology includes companies focused on blood disorders, bone marrow disease, hemoglobinopathies, clotting disorders, and hematologic cancers. Businesses grouped here often sit at the intersection of rare disease, oncology, and precision medicine.

Companies currently grouped under Hematology: 13

## Recent Sector News

- 2026-10-07 13:36 EST — RCKT — [Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-highlights-fda-aligned-pivotal-phase-2-trial-and-updated--fc3517ad) — Source: Rocket Pharmaceuticals
- 2026-10-06 20:12 EST — RCKT — [Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-secures-strategic-credit-facility-for-up-to-150-million-f-92e85216) — Source: Rocket Pharmaceuticals
- 2026-10-02 12:05 EST — RIGL — [Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule--05690942) — Source: Rigel Pharmaceuticals
- 2026-10-01 21:10 EST — ZNTL — [Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5-c82f1cd0) — Source: Zentalis
- 2026-10-01 20:05 EST — KPTI — [Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635--9324267d) — Source: Karyopharm Therapeutics
- 2026-09-24 12:05 EST — APVO — [Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development](https://biopharmsignal.com/news/APVO/aptevo-advances-next-generation-trispecific-candidate-toward-clinical-developmen-9698340e) — Source: Aptevo Therapeutics
- 2026-09-18 20:01 EST — GERN — [Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-e2212861) — Source: Geron
- 2026-09-15 11:00 EST — RCKT — [Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-fda-alignment-on-path-to-complete-pivotal-phase-48ec411b) — Source: Rocket Pharmaceuticals
- 2026-09-15 11:00 EST — RCKT — [Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-fda-alignment-on-path-to-complete-pivotal-phase-3c3da42c) — Source: Rocket Pharmaceuticals
- 2026-09-09 23:25 EST — IRON — [Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-initial-results-from-restore-pv-phase-2-trial-in-patients-718b0075) — Source: Disc Medicine
- 2026-09-03 12:05 EST — APVO — [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML](https://biopharmsignal.com/news/APVO/aptevo-reports-93-clinical-benefit-rate-with-mipletamig-triplet-in-difficult-to--ae677d78) — Source: Aptevo Therapeutics
- 2026-09-03 11:00 EST — RCKT — [Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-to-participate-in-upcoming-investor-conferences-361312c9) — Source: Rocket Pharmaceuticals
- 2026-09-03 11:00 EST — RCKT — [Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-to-participate-in-upcoming-investor-conferences-bbefd532) — Source: Rocket Pharmaceuticals
- 2026-09-02 20:05 EST — ZNTL — [Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences-0168eeb1) — Source: Zentalis
- 2026-09-02 12:05 EST — RIGL — [Rigel to Participate in Upcoming September Investor Conferences](https://biopharmsignal.com/news/RIGL/rigel-to-participate-in-upcoming-september-investor-conferences-ea3b8424) — Source: Rigel Pharmaceuticals
- 2026-09-02 12:00 EST — IRON — [Disc Medicine to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/IRON/disc-medicine-to-participate-in-upcoming-investor-conferences-d0ac8f2b) — Source: Disc Medicine
- 2026-09-02 12:00 EST — GERN — [Geron to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/GERN/geron-to-present-at-upcoming-investor-conferences-170d1dbc) — Source: Geron
- 2026-09-01 21:15 EST — ZNTL — [Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5-e0f2097c) — Source: Zentalis
- 2026-09-01 20:05 EST — KPTI — [Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-0f68dfcc) — Source: Karyopharm Therapeutics
- 2026-09-01 11:00 EST — SNDX — [Syndax Announces Participation in September Investor Conferences](https://biopharmsignal.com/news/SNDX/syndax-announces-participation-in-september-investor-conferences-e9428694) — Source: Syndax Pharmaceuticals

## Companies

- [APVO](https://biopharmsignal.com/company/APVO) — Aptevo Therapeutics
- [APTO](https://biopharmsignal.com/company/APTO) — Aptose Biosciences, Inc.
- [CASI](https://biopharmsignal.com/company/CASI) — CASI Pharmaceuticals Inc
- [IRON](https://biopharmsignal.com/company/IRON) — Disc Medicine
- [GMDA](https://biopharmsignal.com/company/GMDA) — Gamida Cell
- [GERN](https://biopharmsignal.com/company/GERN) — Geron
- [KPTI](https://biopharmsignal.com/company/KPTI) — Karyopharm Therapeutics
- [PRPO](https://biopharmsignal.com/company/PRPO) — Precipio Diagnostics
- [RIGL](https://biopharmsignal.com/company/RIGL) — Rigel Pharmaceuticals
- [RCKT](https://biopharmsignal.com/company/RCKT) — Rocket Pharmaceuticals
- [SLN](https://biopharmsignal.com/company/SLN) — Silence Therapeutics
- [SNDX](https://biopharmsignal.com/company/SNDX) — Syndax Pharmaceuticals
- [ZNTL](https://biopharmsignal.com/company/ZNTL) — Zentalis